BMS, AbbVie Announce EC Approval of Empliciti For Multiple Myeloma
Bristol-Myers Squibb (BMS) Company and AbbVie have announced that the European Commission (EC) has approved Empliciti™ (elotuzumab) for the treatment of multiple…
News
ICER Analyzes Cost and Value of Drugs Used to Treat Multiple Myeloma in New Report
The Institute for Clinical and Economic Review (ICER), an independent nonprofit based in Boston that analyzes the value of drugs and other medical services, has released a…
Phase 3 Study of Ixazomib in Select Multiple Myeloma Patients Reports Benefits
Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib), combined with lenalidomide and dexamethasone as a therapeutic approach for relapsed and/or refractory multiple myeloma (MM), markedly…
Researchers Develop New Animal Model of Multiple Myeloma
Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma,…
Potential Therapeutic Target for Drug-resistant Multiple Myelomas Identified in Study
A subunit of a signaling protein may be a new therapeutic target in multiple myeloma (MM), a hematologic malignancy with high relapse rates and resulting drug resistance in patients, according…
New Adjuvant Therapy Shows Promising Results to Treat Multiple Myeloma, B-Cell Malignancies
A new class of drugs that activate a protein in cells’ endoplasmic reticulum may be used as an adjuvant therapy to treat B-cell malignancies, according to the…
Disrupting Specific Protein May Be Effective Multiple Myeloma Treatment Strategy
Researchers at Buffalo, New York-based Roswell Park Cancer Institute revealed that knocking down individual RabGTPases (Rab) proteins in myeloma cells was sufficient to disrupt the trafficking of…
Protein Identified that May Point to Myeloma Patients Likely to Respond to Proteasome Inhibitors
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with other institutions, identified a gene called TJP1 that could help predict which…
Takeda Publishes Promising Trial Results on Ixazomib, an Approved Drug to Treat Relapsed Multiple Myeloma
Takeda Pharmaceutical has published promising data from the TOURMALINE-MM1 Phase 3 clinical trial of patients with relapsed and/or refractory multiple myeloma (MM), treated with the combination…
International Myeloma Foundation Funds First Broad Screening of Disease at Earliest Stage
The International Myeloma Foundation (IMF) has announced new funding for the first comprehensive screening study that aims to prevent myeloma before it develops. The funded study, titled “iStopMM (Iceland…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL